Here are the principal “slide deck” visuals used to introduce Imagion Biosystems to investors prior to the company’s initial public offering on the Australian Securities Exchange. (download 4.1 MB pdf)
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has